• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

世界卫生组织第五版肺癌诊断指南在三级医疗中心小肺活检中的应用:病理学家对准确诊断的不安全感是否合理?

Application of the 5th WHO Guidelines for the Diagnosis of Lung Carcinoma in Small Lung Biopsies in a Tertiary Care Center: Is Insecurity of Pathologists for the Accurate Diagnosis Justified?

作者信息

Beckert Manuela, Meyer Christian, Papadopoulos Thomas, Levidou Georgia

机构信息

Department of Pathology, Nuremberg Clinic, Paracelsus Medical University, 90419 Nuremberg, Germany.

出版信息

Diagnostics (Basel). 2024 Sep 21;14(18):2090. doi: 10.3390/diagnostics14182090.

DOI:10.3390/diagnostics14182090
PMID:39335769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11431320/
Abstract

BACKGROUND/OBJECTIVES: The diagnosis of lung carcinoma (LC) is currently performed in small biopsies and according to the WHO classification by using limited stains to spare tissue for molecular testing. This procedure, however, often causes diagnostic uncertainty among pathologists.

METHODS

In this retrospective analysis, we compared the diagnosis made by these guidelines in 288 lung biopsies with that using more stains, as retrieved from our archive. We also compared the results of p63 and p40 immunoexpression and investigated the diagnostic role of p53/Rb1.

RESULTS

In our investigation, we reached a definite diagnosis with a mean number of one stain compared with six stains in the original diagnostic procedure, with a 97.3% concordance rate. Only in the case of metastases, a clear advantage is proven in the use of more stains, especially in the absence of clinical information. We also found a comparable utility of p40 and p63 for the diagnosis of squamous cell carcinoma, despite the higher p63 expression in other histological types. Moreover, normal p53/Rb1 expression could be utilized for the exclusion of small-cell LC.

CONCLUSIONS

Our study confirms the diagnostic certainty achieved by the suggestions of the WHO classification and justifies the potential insecurity in the absence of adequate communication with the treating clinician.

摘要

背景/目的:目前肺癌(LC)的诊断是在小活检标本中进行的,并且根据世界卫生组织(WHO)分类,通过使用有限的染色方法以保留组织用于分子检测。然而,这一过程常常导致病理学家之间的诊断不确定性。

方法

在这项回顾性分析中,我们将这些指南对288例肺活检标本所做出的诊断与从我们的存档中获取的使用更多染色方法所做出的诊断进行了比较。我们还比较了p63和p40免疫表达的结果,并研究了p53/Rb1的诊断作用。

结果

在我们的研究中,平均使用一种染色方法就得出了明确的诊断,而原始诊断程序平均使用六种染色方法,二者的符合率为97.3%。仅在转移瘤的情况下,使用更多染色方法显示出明显优势,尤其是在缺乏临床信息时。我们还发现,尽管在其他组织学类型中p63表达较高,但p40和p63在鳞状细胞癌诊断中的效用相当。此外,正常的p53/Rb1表达可用于排除小细胞肺癌。

结论

我们的研究证实了WHO分类建议所实现的诊断确定性,并说明了在与治疗临床医生缺乏充分沟通的情况下可能存在的不安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/7bea593ec8a7/diagnostics-14-02090-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/3ea3ae271866/diagnostics-14-02090-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/6c3b9a5c1941/diagnostics-14-02090-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/14a8cbe3bfd4/diagnostics-14-02090-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/61cae3942ba5/diagnostics-14-02090-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/b35d3b7a1649/diagnostics-14-02090-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/321bdb70eb8c/diagnostics-14-02090-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/29ea8afcf0c3/diagnostics-14-02090-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/7bea593ec8a7/diagnostics-14-02090-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/3ea3ae271866/diagnostics-14-02090-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/6c3b9a5c1941/diagnostics-14-02090-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/14a8cbe3bfd4/diagnostics-14-02090-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/61cae3942ba5/diagnostics-14-02090-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/b35d3b7a1649/diagnostics-14-02090-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/321bdb70eb8c/diagnostics-14-02090-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/29ea8afcf0c3/diagnostics-14-02090-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8abf/11431320/7bea593ec8a7/diagnostics-14-02090-g008.jpg

相似文献

1
Application of the 5th WHO Guidelines for the Diagnosis of Lung Carcinoma in Small Lung Biopsies in a Tertiary Care Center: Is Insecurity of Pathologists for the Accurate Diagnosis Justified?世界卫生组织第五版肺癌诊断指南在三级医疗中心小肺活检中的应用:病理学家对准确诊断的不安全感是否合理?
Diagnostics (Basel). 2024 Sep 21;14(18):2090. doi: 10.3390/diagnostics14182090.
2
Expression of P40 and P63 in lung cancers using fine needle aspiration cases. Understanding clinical pitfalls and limitations.使用细针穿刺病例检测肺癌中P40和P63的表达。了解临床陷阱和局限性。
J Am Soc Cytopathol. 2016 May-Jun;5(3):123-132. doi: 10.1016/j.jasc.2015.07.002.
3
p40 Immunohistochemistry Is an Excellent Marker in Primary Lung Squamous Cell Carcinoma.p40免疫组化是原发性肺鳞状细胞癌的一种优秀标志物。
J Pathol Transl Med. 2018 Sep;52(5):283-289. doi: 10.4132/jptm.2018.08.14. Epub 2018 Aug 31.
4
p40 (ΔNp63) and keratin 34βE12 provide greater diagnostic accuracy than p63 in the evaluation of small cell lung carcinoma in small biopsy samples.p40(ΔNp63)和角蛋白 34βE12 在小活检样本中小细胞肺癌的评估中比 p63 具有更高的诊断准确性。
Hum Pathol. 2013 Aug;44(8):1479-86. doi: 10.1016/j.humpath.2013.01.011. Epub 2013 Mar 22.
5
Double staining: diagnostic utility in non-small cell lung carcinoma in the era of tissue conservation.双重染色:在组织保存时代对非小细胞肺癌的诊断效用
J Am Soc Cytopathol. 2017 Jul-Aug;6(4):170-175. doi: 10.1016/j.jasc.2017.05.003. Epub 2017 May 19.
6
A targeted expression panel for classification, gene fusion detection and PD-L1 measurements - Can molecular profiling replace immunohistochemistry in non-small cell lung cancer?用于分类、基因融合检测和 PD-L1 检测的靶向表达谱 panel- 分子谱分析能否替代非小细胞肺癌的免疫组织化学?
Exp Mol Pathol. 2022 Apr;125:104749. doi: 10.1016/j.yexmp.2022.104749. Epub 2022 Jan 31.
7
Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification.小活检和细胞学标本中肺癌的诊断:2011 年国际肺癌研究协会/美国胸科学会/欧洲呼吸学会分类的意义。
Arch Pathol Lab Med. 2013 May;137(5):668-84. doi: 10.5858/arpa.2012-0263-RA. Epub 2012 Sep 12.
8
Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.在活检和细胞学标本中使用黏蛋白染色、TTF-1、细胞角蛋白 5/6 和 P63 以及 EGFR 突变分析的面板,对非小细胞肺癌的诊断和 EGFR 状态进行精细化处理。
J Thorac Oncol. 2010 Apr;5(4):436-41. doi: 10.1097/JTO.0b013e3181c6ed9b.
9
Application of International association for the study of lung cancer/American Thoracic Society/European Respiratory Society criteria for the diagnosis of lung carcinomas on small biopsies: A tertiary care center experience.国际肺癌研究协会/美国胸科学会/欧洲呼吸学会标准在小活检肺癌诊断中的应用:一家三级医疗中心的经验
South Asian J Cancer. 2019 Jul-Sep;8(3):191-194. doi: 10.4103/sajc.sajc_163_18.
10
p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma.p40(ΔNp63)在诊断肺鳞状细胞癌方面优于 p63。
Mod Pathol. 2012 Mar;25(3):405-15. doi: 10.1038/modpathol.2011.173. Epub 2011 Nov 4.

本文引用的文献

1
The role of immunotherapy in early-stage and metastatic NSCLC.免疫疗法在早期和转移性 NSCLC 中的作用。
Pathol Oncol Res. 2024 Jul 4;30:1611713. doi: 10.3389/pore.2024.1611713. eCollection 2024.
2
Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis.程序性死亡配体 1 表达阴性可切除非小细胞肺癌患者需要新辅助免疫治疗吗?系统评价和荟萃分析。
Lung Cancer. 2024 May;191:107799. doi: 10.1016/j.lungcan.2024.107799. Epub 2024 Apr 23.
3
Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.
程序性死亡配体-1 和肿瘤突变负担检测用于选择肺癌免疫检查点抑制剂治疗的患者:美国病理学家学院、分子病理学协会、国际肺癌研究协会、肺病理学学会和 LUNGevity 基金会的指南。
Arch Pathol Lab Med. 2024 Jul 1;148(7):757-774. doi: 10.5858/arpa.2023-0536-CP.
4
Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review.程序性死亡配体1表达阴性的晚期非小细胞肺癌的免疫治疗:文献综述
Transl Lung Cancer Res. 2024 Feb 29;13(2):398-422. doi: 10.21037/tlcr-23-144. Epub 2024 Feb 28.
5
P53 and Rb Aberrations in Small Cell Lung Cancer (SCLC): From Molecular Mechanisms to Therapeutic Modulation.小细胞肺癌(SCLC)中的P53和Rb畸变:从分子机制到治疗调控
Int J Mol Sci. 2024 Feb 20;25(5):2479. doi: 10.3390/ijms25052479.
6
Practical challenges in lung cancer pathology: bedside care to treatment decisions.肺癌病理学中的实际挑战:从床边护理到治疗决策。
Curr Opin Pulm Med. 2024 Jan 1;30(1):48-57. doi: 10.1097/MCP.0000000000001034. Epub 2023 Nov 8.
7
Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas.探讨肺高级别神经内分泌癌的分子特征和遗传预后因素。
Hum Pathol. 2023 Dec;142:81-89. doi: 10.1016/j.humpath.2023.09.002. Epub 2023 Sep 22.
8
Spotlight on Small-Cell Lung Cancer and Other Lung Neuroendocrine Neoplasms.聚焦小细胞肺癌和其他肺神经内分泌肿瘤。
Am Soc Clin Oncol Educ Book. 2023 May;43:e390794. doi: 10.1200/EDBK_390794.
9
Immunotherapy in Lung Cancer: Current Landscape and Future Directions.肺癌的免疫治疗:现状与未来方向。
Front Immunol. 2022 Feb 9;13:823618. doi: 10.3389/fimmu.2022.823618. eCollection 2022.
10
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015.2021 年世卫组织肺肿瘤分类:自 2015 年以来的进展影响。
J Thorac Oncol. 2022 Mar;17(3):362-387. doi: 10.1016/j.jtho.2021.11.003. Epub 2021 Nov 20.